What is…Iatrogenic injury and why does psychiatric medication come with black box warnings

Iatrogenic injury is harm caused by medical treatment. The word comes from the idea of something being “doctor-caused” or “treatment-caused.” It does not necessarily mean that a doctor acted maliciously or even negligently. A treatment can be properly prescribed, legally approved, and sincerely intended to help, while still producing injury. Surgery can save a life and also cause complications. Chemotherapy can fight cancer and also damage healthy tissue. In the same way, psychiatric medication may reduce certain symptoms for some people while also carrying the possibility of serious adverse effects. When harm comes from the treatment rather than from the original condition, that harm is called iatrogenic.

This distinction is important because many people think of medication side effects as minor annoyances: dry mouth, sleepiness, nausea, or fatigue. But iatrogenic injury is a broader and more serious category. It can include lasting neurological effects, dependency, withdrawal syndromes, suicidality, metabolic changes, organ toxicity, severe allergic reactions, or death. In psychiatry, examples may include neuroleptic-induced tardive dyskinesia, benzodiazepine dependence and withdrawal, antidepressant-associated suicidal thinking in younger patients, lithium toxicity, or severe skin reactions from mood stabilizers such as lamotrigine. These are not merely theoretical concerns. They are recognized risks in official medication labeling.

“Psychiatric medications have several well-known boxed warnings. Antidepressants carry warnings about increased risk of suicidal thoughts and behaviors in children, adolescents, and young adults.”

This is where FDA black box warnings become important. The FDA’s official term is “boxed warning,” but many people call it a “black box warning” because the warning appears inside a bold black border in the prescribing information. A boxed warning is the strongest warning the FDA requires for a prescription medication that is still allowed to remain on the market. It is used when a drug carries a serious risk that doctors and patients must consider before use. In other words, the warning does not mean the drug is banned, but it does mean the government has determined that the risk is serious enough to be placed in the most prominent warning section of the label.

Psychiatric medications have several well-known boxed warnings. Antidepressants carry warnings about increased risk of suicidal thoughts and behaviors in children, adolescents, and young adults. Antipsychotic medications carry warnings about increased mortality in elderly patients with dementia-related psychosis. Benzodiazepines carry warnings about abuse, misuse, addiction, physical dependence, and withdrawal reactions. Prescription stimulants carry warnings about misuse, abuse, addiction, overdose, and death. Lithium carries a warning about toxicity that can occur near therapeutic blood levels. Lamotrigine carries a warning about serious skin rashes, including life-threatening reactions such as Stevens-Johnson syndrome and toxic epidermal necrolysis.

The connection between iatrogenic injury and FDA boxed warnings is therefore direct. A boxed warning is a formal recognition that a medication can cause serious treatment-induced harm. It is not merely a legal technicality. It is part of the informed consent process. Before a person takes a psychiatric medication, he should be told not only what the drug may help with, but also what injuries it may cause. A patient cannot truly consent to treatment if he is told only the hoped-for benefit and not the recognized dangers.

At the same time, a boxed warning should not be misunderstood. It does not prove that every person who takes the medication will be harmed. It does not prove that the drug never has a legitimate use. It does not mean every prescription is malpractice. Rather, it means the medication carries a serious enough risk that careful prescribing, patient education, monitoring, and periodic reassessment are necessary. The honest question is not simply, “Is this drug good or bad?” The better question is, “What are the possible benefits, what are the known risks, what alternatives exist, how long should this be used, and what is the plan if the medication itself begins causing problems?”

This is especially important in psychiatry because the line between original symptoms and medication-induced symptoms can become blurred. A drug may cause agitation, emotional blunting, insomnia, sexual dysfunction, movement disorders, cognitive dulling, dependence, or withdrawal symptoms. If those effects are mistaken for the return or worsening of the original disorder, the patient may be given higher doses or additional medications when the treatment itself may be contributing to the problem. Recognizing iatrogenic injury allows patients, families, and clinicians to ask a necessary question: could the treatment itself be part of the suffering?

The existence of FDA boxed warnings on psychiatric medications should therefore produce humility. It should make prescribers slower to minimize patient concerns. It should make patients more careful to ask informed questions. It should make families attentive to changes that emerge after starting, increasing, decreasing, or stopping medication. And it should challenge the simplistic idea that psychiatric medications are merely correcting a harmless chemical imbalance. These medications act powerfully on the body and brain, and powerful treatments can produce powerful harms.

In the end, iatrogenic injury reminds us that medicine is not morally or physically neutral. Treatment can help, but treatment can also hurt. FDA black box warnings are one official way of acknowledging that reality. They do not settle every debate about psychiatric medication, but they do establish one crucial point: serious medication-induced injury is real, recognized, and important enough that patients must be warned.